

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 February 2024 (01.02.2024)



(10) International Publication Number
WO 2024/026127 A2

(51) International Patent Classification:

A61K 35/17 (2015.01) C07K 14/705 (2006.01)

(21) International Application Number:

PCT/US2023/029047

(22) International Filing Date:

28 July 2023 (28.07.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/393,787 29 July 2022 (29.07.2022) US

(71) Applicant: ADICET THERAPEUTICS, INC. [US/US];
1000 Bridge Parkway, Redwood City, CA 94065 (US).

(72) Inventors: AFTAB, Blake; c/o Adicet Therapeutics, Inc.,
1000 Bridge Parkway, Redwood City, CA 94065 (US). BHAT, Arun; c/o Adicet Therapeutics, Inc., 1000 Bridge
Parkway, Redwood City, CA 94065 (US). NISHIMOTO,
Kevin; c/o Adicet Therapeutics, Inc., 1000 Bridge Park-
way, Redwood City, CA 94065 (US). TEAGUE, Alexan-
der; c/o Adicet Therapeutics, Inc., 1000 Bridge Parkway,
Redwood City, CA 94065 (US). SPELTZ, Elizabeth; c/
o Adicet Therapeutics, Inc., 1000 Bridge Parkway, Red-
wood City, CA 94065 (US). LAMTURE, Gauri; c/o Adicet
Therapeutics, Inc., 1000 Bridge Parkway, Redwood City,
CA 94065 (US). DING, Beibei; c/o Adicet Therapeutics,
Inc., 1000 Bridge Parkway, Redwood City, CA 94065 (US).
RAMADOSS, Nitya; c/o Adicet Therapeutics, Inc., 1000
Bridge Parkway, Redwood City, CA 94065 (US).

(74) Agent: LORENZ, Todd et al.; Squire Patton Boggs, 555
California Street, Suite 550, San Francisco, CA 94104 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

WO 2024/026127 A2

(54) Title: AFFINITY BINDING ENTITIES DIRECTED TO CD70 AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure include compositions and methods for the treatment of CD70-expressing tumors with engi-
neered $\gamma\delta$ T-cells. In embodiments, the $\gamma\delta$ T-cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can include
a full-length CD27 receptor domain, a costimulatory domain, an intracellular signaling domain, a combination thereof, or all thereof. The
CAR construct can contain a domain encoding for an additional polypeptide that confers advantageous functionality to the $\gamma\delta$ T- cells.